

PRESS RELEASE


RESEARCH & INNOVATION IN NUCLEAR MEDICINE

**DOSIsoft & AP-HP: a scientific partnership on « QUANTHYR » - 1<sup>st</sup> software dedicated to personalized diagnosis and dosimetry treatment of hyperthyroidism with <sup>131</sup>Iodine**


To improve cancer patient safety and treatment quality, DOSIsoft, leading provider of patient-specific software solutions in Radiation Oncology & Nuclear Medicine, distributed in more than 60 countries, announces that it has signed a development and commercialization agreement (license) with the Assistance Publique – Hôpitaux de Paris (AP-HP) for a Radioiodine theranostic solution applied to benign thyroid diseases named "QUANTHYR".

« QUANTHYR »: an innovation patented\* for the personalized treatment of hyperthyroidism diseases

Many years of research conducted by Professor Jérôme Clerc, head of nuclear medicine department at Cochin hospital - AP-HP, have resulted in the creation of "QUANTHYR" solution, which aims to optimize the diagnostic and prognostic performance of thyroid scintigraphy images. This application simplifies the personalization of iodine-131 prescriptions, making them individualized from a clinical perspective and optimized from a dosimetric perspective, regardless of the type of hyperthyroidism.



For the first time, "QUANTHYR" enables direct visualization of the dose distribution in the thyroid, corresponding to the prescribed iodine-131 activities (in this case, 296 MBq prescribed, with an average absorbed dose of 100 Gy).



\*Patent issued in France, entitled "Method and device for image processing in thyroid scintigraphy"

"QUANTHYR" facilitates the Iodine-131 radiopharmaceutical prescription process and helps limit the level of administered activity, which is required in radiation protection. Finally, the quantified data generated by the imaging software will pave the way for a more precise classification of the different types of hyperthyroidism, powered by AI (neural networks).

Under the protection and value-added proposal from the Transfer and Innovation Division team within the AP-HP Clinical Research and Innovation Department, the innovation is based on two "prototype" software programs used exclusively for research purposes: **the first is dedicated to imaging & diagnosis and the second is focused on individualized dosimetry therapy.**

In 2021, "QUANTHYR" was also awarded in the first session of the "Booster Innovation" call for projects launched by AP-HP, aimed at professionals. This initiative sought to develop and industrialize an integrated solution for the personalized treatment of hyperthyroidism.

### DOSIsoft & AP-HP: a close collaboration on technology transfer and commercial development of "QUANTHYR"

Leveraging its expertise in medical imaging and dosimetry acquired over more than 20 years, DOSIsoft was initially selected as a specialized software provider and subsequently as a preferred partner to support AP-HP in the successful development, clinical evaluation and commercialization of the new "QUANTHYR" module.

Supported by the DOSIsoft team, the "QUANTHYR" module has been integrated into PLANET<sup>®</sup> Dose – a dosimetry platform dedicated to treatment planning and follow-up through Radionuclide Molecular Radiotherapy (MRT). This integration enhances PLANET<sup>®</sup> Dose by introducing a new application for the personalized management of patients with benign thyroid diseases.

DOSIsoft S.A.'s business development plan includes a clinical evaluation phase involving partner centers, a pre-launch phase featuring various congresses in France and the submission and attainment of CE mark.

*"We're enthusiastic about the opportunity to help physicians and patients with benign thyroid pathology benefit from personalized treatment. PLANET<sup>®</sup> Dose-QUANTHYR represents a unique innovation in the world, aligning with our vision of personalized medicine, and reinforcing our commitment to physicians towards the benefit of patients",* says Marc USZYNSKI, CEO at DOSIsoft S.A.

*"The introduction of quantification in thyroid scintigraphy images, combined with biological and echography volumetry, provides an unparalleled reproducible diagnostic power. By placing the clinical therapeutic objective at the center of the approach, prescribing becomes more accessible and straightforward. QUANTHYR also serves as a radioprotection tool, minimizing activity levels and securing the radiopharmaceutical prescription process",* says Pr Jérôme CLERC, Head of the Nuclear Medicine department at Cochin hospital - AP-HP.

### About Assistance Publique - Hôpitaux de Paris / Greater Paris University Hospitals

The leading hospital and university centre (CHU) in Europe, Greater Paris University Hospitals and its 38 hospitals are organized into six hospital-university groups (AP-HP. Centre - Université Paris Cité ; AP-HP. Sorbonne Université ; AP-HP. Nord - Université Paris Cité ; AP-HP. Université Paris Saclay ; AP-HP. Hôpitaux Universitaires Henri Mondor et AP-HP. Hôpitaux Universitaires Paris Seine-Saint-Denis) and are centered around five universities in the Île-de-France region. Closely linked to large research bodies, Greater Paris University Hospitals include eight international hospital-university institutes (Institut du Cerveau, ICAN, IMAGINE, FOrEoSIGHT, PROMETHEUS, InovAND, reConnect, THEMA) and the largest French health data repository (EDS). As a major stakeholder in applied research and health innovation, Greater Paris University Hospitals hold a portfolio of 750 active patents, and each year its clinicians sign off nearly 11000 scientific publications and over 4,000 research projects are under development, all promoters combined. In 2020, Greater Paris University Hospitals were awarded the Institut Carnot label, which is recognition of the quality of partner research: Carnot@AP-HP offers industrial stakeholders applied and clinical research solutions in the health sector. In 2015, Greater Paris University Hospitals also founded the Greater Paris University Hospitals Research Foundation to support the biomedical and health research performed in all its hospitals. <http://www.aphp.fr>

Press contact AP-HP Press Department | +33 (0)1 40 27 37 22 | [service.presse@aphp.fr](mailto:service.presse@aphp.fr)



### About DOSIsoft

Founded in 2002, DOSIsoft designs, develops & delivers patient-specific imaging & dosimetry software solutions for Radiation Oncology & Nuclear Medicine, aimed at improving cancer patient safety & treatment quality. More than 20 years of innovation and R&D investments have led to world leading software used in over 600 hospital centers in 60 countries. Spin-off between Gustave Roussy and Institut Curie, DOSIsoft constantly innovates in partnership with the major cancer institutes and research centres in the world. [www.dosisoft.com](http://www.dosisoft.com)

Press contact Xiaolu CHEN | [xiaolu.chen@dosisoft.com](mailto:xiaolu.chen@dosisoft.com)  
DOSIsoft SA +33 (0)1 41 24 26 26 | 45/47, Avenue Carnot, 94230 Cachan – France  
DOSIsoft Inc. +1 (844) 772-3674 | 2525 Ponce de Leon Ste 300, Coral Gables, FL 33134 – USA